You are here

Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions.

TitleRecognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions.
Publication TypeJournal Article
Year of Publication1998
AuthorsKoelle, DM, Frank, JM, Johnson, ML, Kwok, WW
JournalJ Virol
Volume72
Issue9
Pagination7476-83
Date Published1998 Sep
ISSN0022-538X
KeywordsAmino Acid Sequence, Animals, Antigens, Viral, CD4-Positive T-Lymphocytes, Cell Line, Transformed, Cercopithecus aethiops, Cloning, Molecular, Epitopes, T-Lymphocyte, Herpes Genitalis, Herpes Simplex Virus Protein Vmw65, Herpesvirus 2, Human, HLA-DQ Antigens, HLA-DQ beta-Chains, Humans, Molecular Sequence Data, Pyrophosphatases, Recombinant Fusion Proteins, Vero Cells, Viral Structural Proteins
Abstract

The local cellular immune response to herpes simplex virus (HSV) is important in the control of recurrent HSV infection. The antiviral functions of infiltrating CD4-bearing T cells may include cytotoxicity, inhibition of viral growth, lymphokine secretion, and support of humoral and CD8 responses. The antigens recognized by many HSV-specific CD4 T cells localizing to genital HSV-2 lesions are unknown. T cells recognizing antigens encoded within map units 0. 67 to 0.73 of HSV DNA are frequently recovered from herpetic lesions. Expression cloning with this region of DNA now shows that tegument protein VP22 and the viral dUTPase, encoded by genes UL49 and UL50, respectively, are T-cell antigens. Separate epitopes in VP22 were defined for T-cell clones from each of three patients. Reactivity with the tegument protein encoded by UL21 was identified for an additional patient. Three new epitopes were identified in VP16, a tegument protein associated with VP22. Some tegument-specific CD4 T-cell clones exhibited cytotoxic activity against HSV-infected cells. These results suggest that herpes simplex tegument proteins are processed for antigen presentation in vivo and are possible candidate compounds for herpes simplex vaccines.

Alternate JournalJ. Virol.
PubMed ID9696844